Use of Positron Emission Tomography for Proton Therapy Verification

Total Page:16

File Type:pdf, Size:1020Kb

Use of Positron Emission Tomography for Proton Therapy Verification The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 5-2014 USE OF POSITRON EMISSION TOMOGRAPHY FOR PROTON THERAPY VERIFICATION Jongmin Cho Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Nuclear Commons, and the Radiology Commons Recommended Citation Cho, Jongmin, "USE OF POSITRON EMISSION TOMOGRAPHY FOR PROTON THERAPY VERIFICATION" (2014). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 435. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/435 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. USE OF POSITRON EMISSION TOMOGRAPHY FOR PROTON THERAPY VERIFICATION by Jongmin Cho, B.E., M.S. APPROVED: _____________________________________ Supervisory Professor, Geoffrey Ibbott, Ph.D _____________________________________ Osama Mawlawi, Ph.D _____________________________________ Michael Gillin, Ph.D _____________________________________ Carlos Gonzalez-Lepera, Ph.D _____________________________________ Francesco Stingo, Ph.D _____________________________________ Harald Paganetti, Ph.D APPROVED: __________ __________________ Dean, The University of Texas Graduate School of Biomedical Sciences at Houston USE OF POSITRON EMISSION TOMOGRAPHY FOR PROTON THERAPY VERIFICATION A DISSERTATION Presented to the Faculty of The University of Texas Health Science Center at Houston and The University of Texas MD Anderson Cancer Center Graduate School of Biomedical Sciences in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY by Jongmin Cho, B.E., M.S. HOUSTON, TEXAS May, 2014 © Copyright by Jongmin Cho 2014 All Rights Reserved iv DEDICATION I dedicate my dissertation work to my wife Rachel whose love and support lifted me from start to finish; my mother, Soonin who always sacrificed herself for the well-being of her children; my father, Youngbae whose perseverance and quest for knowledge inspired me, and to my three elder sisters, Jungim, Jungsun, and Hyunjoo who always looked after their younger brother. My sincerest dedication goes to those suffering from cancer and those who suffer alongside them. This work is especially dedicated to God the Father, God the Son, and God the Holy Spirit Who provided me research ideas, strength to continue, and surrounding me with wonderful people who made my research possible. “The Lord is my light and my salvation; whom shall I fear? The Lord is the strength of my life; of whom shall I be afraid?” – Psalm 27:1 v ACKNOWLEDGEMENTS First and foremost, I wish to express my heartfelt gratitude to my mentors, Drs. Geoffrey Ibbott and Osama Mawlawi who generously supported me financially and provided me ample amount of time and opportunities. Although this dissertation is an important fruit of great relationships with both mentors, they taught and sow something as important – great leadership and mentorship which I may bear fruit after graduation. I would like to acknowledge and thank my former research mentor, Dr. Reinhard Schulte at Loma Linda University for his unfailing support that spanned almost a decade. I would also like to thank Dr. Pablo Yepes from Rice University and Dr. Uwe Titt for their great support with the Monte Carlo simulation. Thank you to Dr. Michael Gillin, Richard Amos and Matthew Kerr for their expertise of proton measurements. Thank you to Drs. Carlos Gonzalez-Lepera and Francesco Stingo for their advice and help with their expertise which was essential for this dissertation. Many thanks to the departments of Radiation Oncology and Radiology at Massachusetts General Hospital, with a special thanks to Drs. Harald Paganetti and ChulHee Min who have been pivotal in the collaborations between Massachusetts General Hospital and MD Anderson Cancer Center. Last, but not least, I would like to thankfully acknowledge my colleagues, staff and faculty members - Dr. Pan, Dr. Wendt, Dr. Sahoo, Moiz, Kevin Casey, Kevin Vredevoogd, Mitchell, Ryan, Lawrence, Paige, Paul Wisdom, Frances, Bryan Steward, Justin, Rachael, Majid, Shuaiping and many others who played an integral part in my dissertation. vi USE OF POSITRON EMISSION TOMOGRAPHY FOR PROTON THERAPY VERIFICATION Jongmin Cho, B.E., M.S. Supervisory Professor: Geoffrey Ibbott, Ph.D. Positron emission tomography (PET), a tool commonly used for cancer staging and response monitoring, has recently been used for proton therapy verification. By imaging tissue activation following proton treatment, attempts have been made to verify proton dose and range . In this dissertation, two novel approaches were developed and tested for the purpose of help improve the proton dose and range estimation as well as verification. Although there are still some challenges, attempts for proton dose verification using PET has been made by comparing Monte Carlo dose and PET simulations with treatment planned dose and measured PET. In this approach, generic tissue composition information is used which can cause large uncertainties in Monte Carlo PET simulation. To improve these uncertainties, we developed a method in the first part of the research to obtain tissue elemental composition using PET after proton therapy. Proton activation of tissue creates progeny radioisotopes according to constituting tissue elements’ cross sections and proton energies. The time-activity-curves from activated tissues can be separated into constituting progeny radioisotopes using a least squares method and then to constituting elemental compositions using Monte Carlo simulated proton energy and cross-section information. We tested this approach using a phantom consisting of sections composed of different combinations of 12 C and 16 O irradiated using a mono-energetic and a SOBP proton beam. In vii addition, two patient studies were also evaluated using the same technique immediately after proton treatments. The 12 C and 16 O compositions were estimated within 3.6% accuracy in the phantom studies and within 15.2% for patient studies. The obtained tissue elemental composition can be used to improve proton dose verification using PET. In the second part of this dissertation, we developed a new approach to verify proton range. Conventional proton range verification is performed by correlating the distal end of measured PET signals to the proton range. However, this approach is affected by minimal tissue activation near the end of the proton range, perfusion-driven activity washout, and short half-lives of progeny radioisotopes. This also requires an in-beam, in-room, or on-site PET scanner which can be financially and technically challenging for many proton centers. Our new approach overcomes all of these limitations by using proton activated markers. When implanted near the proton distal end, those markers are strongly activated while tissues are minimally activated. For this work we tested 18 O enriched water, Cu and 68 Zn enriched markers that were embedded in tissue-equivalent materials and imaged using an off-site PET scanner following proton activation. The marker materials provided significantly stronger PET signals near the distal end which can be used to verify proton range. In addition, optimal volumes of those markers were also investigated when imbedded in tissue-equivalent materials while using clinical treatment and imaging scenarios. Our results suggest that marker volumes ranging between 5 and 50 mm 3 are required to provide adequate PET signals. The proposed approach can potentially replace conventional fiducial markers with the added benefit of proton range verification. Two proposed methods performed in this research can be used potentially improve both proton dose verification using PET and proton range verification using an off-site PET. viii Contents __________________________________________________________________________ Dedication ………………………………………………………………………..……... V Acknowledgements ……………………………………………………………………. VI Abstract …………………………………………………………………………........ VII Contents ……………………………………….………………………………………. IX List of Figures …………………………………………………………………………. XI List of Tables ………………………………………………………………………… XVI List of Abbreviations ………………………………………………………........... XVIII 1 Introduction …………………………………………………………………………. 1 1.1 Hypothesis …………………………………………………………………… 2 1.2 Specific Aims ……………………………………………………………….... 3 1.3 Dissertation Organization ……………………………………………………. 4 2 Background …………………………………………………………………………. 6 2.1 Proton Therapy ………………………………………………………………. 6 2.2 Proton Therapy Verifications ……………………………………………....... 9 3 Determination of Elemental Tissue Composition following Proton Treatment using Positron Emission Tomography ………………………………………………….. 13 3.1 Introduction …………………………………………………………………. 13 3.2 Materials and Methods ……………………………………………………... 15 3.2.1 Phantom Activation and PET Imaging …………………………. 15 3.2.2 Method of Decoupling Decay Curves
Recommended publications
  • Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs
    Guidance Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs GUIDANCE U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) December 2012 Clinical/Medical Guidance Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs Additional copies are available from: Office of Communications Division of Drug Information, WO51, Room 2201 Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave. Silver Spring, MD 20993-0002 Phone: 301-796-3400; Fax: 301-847-8714 [email protected] http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) December 2012 Clinical/Medical Contains Nonbinding Recommendations TABLE OF CONTENTS I. INTRODUCTION..............................................................................................................................................1 II. BACKGROUND ................................................................................................................................................1 A. PET DRUGS .....................................................................................................................................................1 B. IND..................................................................................................................................................................2
    [Show full text]
  • Chapter 3 the Fundamentals of Nuclear Physics Outline Natural
    Outline Chapter 3 The Fundamentals of Nuclear • Terms: activity, half life, average life • Nuclear disintegration schemes Physics • Parent-daughter relationships Radiation Dosimetry I • Activation of isotopes Text: H.E Johns and J.R. Cunningham, The physics of radiology, 4th ed. http://www.utoledo.edu/med/depts/radther Natural radioactivity Activity • Activity – number of disintegrations per unit time; • Particles inside a nucleus are in constant motion; directly proportional to the number of atoms can escape if acquire enough energy present • Most lighter atoms with Z<82 (lead) have at least N Average one stable isotope t / ta A N N0e lifetime • All atoms with Z > 82 are radioactive and t disintegrate until a stable isotope is formed ta= 1.44 th • Artificial radioactivity: nucleus can be made A N e0.693t / th A 2t / th unstable upon bombardment with neutrons, high 0 0 Half-life energy protons, etc. • Units: Bq = 1/s, Ci=3.7x 1010 Bq Activity Activity Emitted radiation 1 Example 1 Example 1A • A prostate implant has a half-life of 17 days. • A prostate implant has a half-life of 17 days. If the What percent of the dose is delivered in the first initial dose rate is 10cGy/h, what is the total dose day? N N delivered? t /th t 2 or e Dtotal D0tavg N0 N0 A. 0.5 A. 9 0.693t 0.693t B. 2 t /th 1/17 t 2 2 0.96 B. 29 D D e th dt D h e th C. 4 total 0 0 0.693 0.693t /th 0.6931/17 C.
    [Show full text]
  • A New Gamma Camera for Positron Emission Tomography
    INIS-mf—11552 A new gamma camera for Positron Emission Tomography NL89C0813 P. SCHOTANUS A new gamma camera for Positron Emission Tomography A new gamma camera for Positron Emission Tomography PROEFSCHRIFT TER VERKRIJGING VAN DE GRAAD VAN DOCTOR AAN DE TECHNISCHE UNIVERSITEIT DELFT, OP GEZAG VAN DE RECTOR MAGNIFICUS, PROF.DRS. P.A. SCHENCK, IN HET OPENBAAR TE VERDEDIGEN TEN OVERSTAAN VAN EEN COMMISSIE, AANGEWEZEN DOOR HET COLLEGE VAN DECANEN, OP DINSDAG 20 SEPTEMBER 1988TE 16.00 UUR. DOOR PAUL SCHOTANUS '$ DOCTORANDUS IN DE NATUURKUNDE GEBOREN TE EINDHOVEN Dit proefschrift is goedgekeurd door de promotor Prof.dr. A.H. Wapstra s ••I Sommige boeken schijnen geschreven te zijn.niet opdat men er iets uit zou leren, maar opdat men weten zal, dat de schrijver iets geweten heeft. Goethe Contents page 1 Introduction 1 2 Nuclear diagnostics as a tool in medical science; principles and applications 2.1 The position of nuclear diagnostics in medical science 2 2.2 The detection of radiation in nuclear diagnostics: 5 standard techniques 2.3 Positron emission tomography 7 2.4 Positron emitting isotopes 9 2.5 Examples of radiodiagnostic studies with PET 11 2.6 Comparison of PET with other diagnostic techniques 12 3 Detectors for positron emission tomography 3.1 The absorption d 5H keV annihilation radiation in solids 15 3.2 Scintillators for the detection of annihilation radiation 21 3.3 The detection of scintillation light 23 3.4 Alternative ways to detect annihilation radiation 28 3-5 Determination of the point of annihilation: detector geometry,
    [Show full text]
  • Radiation and Risk: Expert Perspectives Radiation and Risk: Expert Perspectives SP001-1
    Radiation and Risk: Expert Perspectives Radiation and Risk: Expert Perspectives SP001-1 Published by Health Physics Society 1313 Dolley Madison Blvd. Suite 402 McLean, VA 22101 Disclaimer Statements and opinions expressed in publications of the Health Physics Society or in presentations given during its regular meetings are those of the author(s) and do not necessarily reflect the official position of the Health Physics Society, the editors, or the organizations with which the authors are affiliated. The editor(s), publisher, and Society disclaim any responsibility or liability for such material and do not guarantee, warrant, or endorse any product or service mentioned. Official positions of the Society are established only by its Board of Directors. Copyright © 2017 by the Health Physics Society All rights reserved. No part of this publication may be reproduced or distributed in any form, in an electronic retrieval system or otherwise, without prior written permission of the publisher. Printed in the United States of America SP001-1, revised 2017 Radiation and Risk: Expert Perspectives Table of Contents Foreword……………………………………………………………………………………………………………... 2 A Primer on Ionizing Radiation……………………………………………………………………………... 6 Growing Importance of Nuclear Technology in Medicine……………………………………….. 16 Distinguishing Risk: Use and Overuse of Radiation in Medicine………………………………. 22 Nuclear Energy: The Environmental Context…………………………………………………………. 27 Nuclear Power in the United States: Safety, Emergency Response Planning, and Continuous Learning…………………………………………………………………………………………….. 33 Radiation Risk: Used Nuclear Fuel and Radioactive Waste Disposal………………………... 42 Radiation Risk: Communicating to the Public………………………………………………………… 45 After Fukushima: Implications for Public Policy and Communications……………………. 51 Appendix 1: Radiation Units and Measurements……………………………………………………. 57 Appendix 2: Half-Life of Some Radionuclides…………………………………………………………. 58 Bernard L.
    [Show full text]
  • Investigation of Dosimetric Effects of Radiopaque Fiducial Markers for Use in Proton Beam Therapy with Film Measurements and Monte Carlo Simulations
    Investigation of dosimetric effects of radiopaque fiducial markers for use in proton beam therapy with film measurements and Monte Carlo simulations Zerrin Uludag Thesis for Master of Science in Medical Radiation Physics 2014-04-10 Supervisors: Anders Montelius and Shirin Enger - 2 - ACKNOWLEDGMENTS I would like to express my sincere gratitude to Professor Anders Ahnesjö for helpful advice. - 3 - ABSTRACT Purpose: To estimate the dose perturbation introduced by implanted radiopaque fiducial markers in proton beam therapy (PBT) depending on the shape, orientation and localization of the marker. The aim was also to make a comparative study between the cylindrical proton gold marker (0.6 mm x 4.0 mm), used today in PBT, the photon marker (1.2 mm x 3.0 mm) and the Gold Anchor marker (0.28 mm x 20.0mm), a new type of marker developed by Naslund Medical AB for use in soft tissue. Background: In radiation therapy (RT), fiducial markers are often used in order to facilitate the tumour localization by using image guided radiation therapy (IGRT). However, the use of x-ray opaque markers in PBT can introduce unacceptable underdosage behind the marker in the target resulting in less effective tumour cell kill. Materials and methods: Radiochromic film measurements and Monte Carlo (MC) calculations based on the Geant4 general-purpose simulation toolkit were used in this work for the estimation of the dose perturbation in presence of fiducial gold markers. The experiments were performed at The Svedberg Laboratory (TSL) which offers proton beams with a passive scattering technique. The fiducials were imbedded into Blue wax and the films were stacked behind the wax between thin PMMA slabs.
    [Show full text]
  • Nuclear Fusion Enhances Cancer Cell Killing Efficacy in a Protontherapy Model
    Nuclear fusion enhances cancer cell killing efficacy in a protontherapy model GAP Cirrone*, L Manti, D Margarone, L Giuffrida, A. Picciotto, G. Cuttone, G. Korn, V. Marchese, G. Milluzzo, G. Petringa, F. Perozziello, F. Romano, V. Scuderi * Corresponding author Abstract Protontherapy is hadrontherapy’s fastest-growing modality and a pillar in the battle against cancer. Hadrontherapy’s superiority lies in its inverted depth-dose profile, hence tumour-confined irradiation. Protons, however, lack distinct radiobiological advantages over photons or electrons. Higher LET (Linear Energy Transfer) 12C-ions can overcome cancer radioresistance: DNA lesion complexity increases with LET, resulting in efficient cell killing, i.e. higher Relative Biological Effectiveness (RBE). However, economic and radiobiological issues hamper 12C-ion clinical amenability. Thus, enhancing proton RBE is desirable. To this end, we exploited the p + 11Bà3a reaction to generate high-LET alpha particles with a clinical proton beam. To maximize the reaction rate, we used sodium borocaptate (BSH) with natural boron content. Boron-Neutron Capture Therapy (BNCT) uses 10B-enriched BSH for neutron irradiation-triggered alpha-particles. We recorded significantly increased cellular lethality and chromosome aberration complexity. A strategy combining protontherapy’s ballistic precision with the higher RBE promised by BNCT and 12C-ion therapy is thus demonstrated. 1 The urgent need for radical radiotherapy research to achieve improved tumour control in the context of reducing the risk of normal tissue toxicity and late-occurring sequelae, has driven the fast- growing development of cancer treatment by accelerated beams of charged particles (hadrontherapy) in recent decades (1). This appears to be particularly true for protontherapy, which has emerged as the most-rapidly expanding hadrontherapy approach, totalling over 100,000 patients treated thus far worldwide (2).
    [Show full text]
  • Positron Emission Tomography
    Positron emission tomography A.M.J. Paans Department of Nuclear Medicine & Molecular Imaging, University Medical Center Groningen, The Netherlands Abstract Positron Emission Tomography (PET) is a method for measuring biochemical and physiological processes in vivo in a quantitative way by using radiopharmaceuticals labelled with positron emitting radionuclides such as 11C, 13N, 15O and 18F and by measuring the annihilation radiation using a coincidence technique. This includes also the measurement of the pharmacokinetics of labelled drugs and the measurement of the effects of drugs on metabolism. Also deviations of normal metabolism can be measured and insight into biological processes responsible for diseases can be obtained. At present the combined PET/CT scanner is the most frequently used scanner for whole-body scanning in the field of oncology. 1 Introduction The idea of in vivo measurement of biological and/or biochemical processes was already envisaged in the 1930s when the first artificially produced radionuclides of the biological important elements carbon, nitrogen and oxygen, which decay under emission of externally detectable radiation, were discovered with help of the then recently developed cyclotron. These radionuclides decay by pure positron emission and the annihilation of positron and electron results in two 511 keV γ-quanta under a relative angle of 180o which are measured in coincidence. This idea of Positron Emission Tomography (PET) could only be realized when the inorganic scintillation detectors for the detection of γ-radiation, the electronics for coincidence measurements, and the computer capacity for data acquisition and image reconstruction became available. For this reason the technical development of PET as a functional in vivo imaging discipline started approximately 30 years ago.
    [Show full text]
  • Radiation and Your Patient: a Guide for Medical Practitioners
    RADIATION AND YOUR PATIENT: A GUIDE FOR MEDICAL PRACTITIONERS A web module produced by Committee 3 of the International Commission on Radiological Protection (ICRP) What is the purpose of this document ? In the past 100 years, diagnostic radiology, nuclear medicine and radiation therapy have evolved from the original crude practices to advanced techniques that form an essential tool for all branches and specialties of medicine. The inherent properties of ionising radiation provide many benefits but also may cause potential harm. In the practice of medicine, there must be a judgement made concerning the benefit/risk ratio. This requires not only knowledge of medicine but also of the radiation risks. This document is designed to provide basic information on radiation mechanisms, the dose from various medical radiation sources, the magnitude and type of risk, as well as answers to commonly asked questions (e.g radiation and pregnancy). As a matter of ease in reading, the text is in a question and answer format. Interventional cardiologists, radiologists, orthopaedic and vascular surgeons and others, who actually operate medical x-ray equipment or use radiation sources, should possess more information on proper technique and dose management than is contained here. However, this text may provide a useful starting point. The most common ionising radiations used in medicine are X, gamma, beta rays and electrons. Ionising radiation is only one part of the electromagnetic spectrum. There are numerous other radiations (e.g. visible light, infrared waves, high frequency and radiofrequency electromagnetic waves) that do not posses the ability to ionize atoms of the absorbing matter.
    [Show full text]
  • Literature Survey on Decorporation of Radionuclides from the Human Body
    Literature Survey on Decorporation of Radionuclides from the Human Body E.A. Waller, R.Z. Stodilka, K. Leach and L. Prud’homme-Lalonde Defence R&D Canada - Ottawa TECHNICAL MEMORANDUM DRDC Ottawa TM 2002-042 April 2002 Literature Survey on Decorporation of Radionuclides from the Human Body E.A. Waller SAIC Canada, Inc R.Z. Stodilka, K. Leach and L. Prud’homme-Lalonde Space Systems and Technology Defence R&D Canada - Ottawa Technical Memorandum DRDC Ottawa TM 2002-042 April 2002 © Her Majesty the Queen as represented by the Minister of National Defence, 2002 © Sa majesté la reine, représentée par le ministre de la Défense nationale, 2002 Abstract The broad use of radionuclides by many industries has greatly increased the probability of events that could lead to internalized contamination. Examples include accidents and/or intentional damage to nuclear power plants or radiation therapy units in hospitals, the use of radiological dispersal weapons, and lost or stolen radionuclide sources. Developing effective countermeasures requires knowledge of the physical and chemical composition of the radionuclides, their metabolic activities within the body, and methods to expedite their elimination from the body. This report presents a summary of information pertaining to intake and decorporation of radionuclides from humans. This information would be the first step in establishing a field protocol to guide physicians in military missions. Developing such a guide requires an understanding of the dangers associated with internal radioisotope contamination, decision levels for administering therapy (risk vs. benefit) and protocols for administering therapy. As presented, this study could be used to decide what decorporation pharmaceuticals should be maintained in quantity by the military, and how to best train officers with medical responsibilities.
    [Show full text]
  • And Stereotactic Body Radiation Therapy (SBRT)
    Geisinger Health Plan Policies and Procedure Manual Policy: MP084 Section: Medical Benefit Policy Subject: Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy I. Policy: Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) II. Purpose/Objective: To provide a policy of coverage regarding Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) III. Responsibility: A. Medical Directors B. Medical Management IV. Required Definitions 1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy. 2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy. 3. Devised – the date the policy was implemented. 4. Revised – the date of every revision to the policy, including typographical and grammatical changes. 5. Reviewed – the date documenting the annual review if the policy has no revisions necessary. V. Additional Definitions Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are: a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury; b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury; c. in accordance with current standards of good medical treatment practiced by the general medical community. d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.
    [Show full text]
  • New Discoveries in Radiation Science
    cancers Editorial New Discoveries in Radiation Science Géza Sáfrány 1,*, Katalin Lumniczky 1 and Lorenzo Manti 2 1 Department Radiobiology and Radiohygiene, National Public Health Center, 1221 Budapest, Hungary; [email protected] 2 Department of Physics, University of Naples Federico II, 80126 Naples, Italy; [email protected] * Correspondence: [email protected]; Tel.: +36-309199218 This series of 16 articles (8 original articles and 8 reviews) was written by internation- ally recognized scientists attending the 44th Congress of the European Radiation Research Society (Pécs, Hungary). Ionizing radiation is an interesting agent because it is used to cure cancers and can also induce cancer. The effects of ionizing radiation at the organism level depend on the response of the cells. When radiation hits a cell, it might damage any cellular organelles and macromolecules. Unrepairable damage leads to cell death, while misrepaired alterations leave mutations in surviving cells. If the repair is errorless, normal cells will survive. However, in a small percentage of the seemingly healthy cells the number of spontaneous mutations will increase, which is a sign of radiation-induced genomic instability. Radiation-induced cell death is behind the development of acute radiation syndromes and the killing of tumorous and normal cells during radiation therapy. Radiation-induced mutations in surviving cells might lead to the induction of tumors. According to the central paradigm of radiation biology, the genetic material, that is the DNA, is the main cellular target of ionizing radiation. Many different types of damage are induced by radiation in the DNA, but the most deleterious effects arise from double strand breaks (DSBs).
    [Show full text]
  • Radiation Therapy
    Radiation Therapy What is radiation therapy? Radiation therapy is the use of high-energy x-rays or other particles to destroy cancer cells. A doctor who uses radiation therapy to treat cancer is called a radiation oncologist. The goal of radiation therapy is to destroy the cancer cells without harming nearby healthy tissue. It may be used along with other cancer treatments or as the main treatment. Sometimes radiation therapy is used to relieve symptoms, called palliative radiation therapy. More than half of all people with cancer receive some type of radiation therapy. What are the different types of radiation therapy? The most common type is called external-beam radiation therapy, which is radiation given from a machine located outside the body. Types of external-beam radiation therapy include proton therapy, 3-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and stereotactic radiation therapy. Sometimes radiation therapy involves bringing a radioactive source close to a tumor. This is called internal radiation therapy or brachytherapy. The type you receive depends on many factors. Learn more about radiation treatment at www.cancer.net/radiationtherapy. What should I expect during radiation therapy? Before treatment begins, you will meet with the radiation oncologist to review your medical history and discuss the potential risks and benefits. If you choose to receive radiation therapy, you may undergo tests to plan the treatment and evaluate the results. Before radiation therapy begins, it must be planned carefully. This planning stage is often called a “simulation.” During this visit, the medical team will figure out the best position for you to be in during treatment.
    [Show full text]